Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 7.8
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of REPL is 12 and suggests 55% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
Buy
Sell